Baig, N. A., Taylor, R. P., Lindorfer, M. A., Church, A. K., LaPlant, B. R., Pavey, E. S., . . . Zent, C. S. (2012). Complement dependent cytotoxicity (CDC) in chronic lymphocytic leukemia (CLL): Ofatumumab enhances alemtuzumab CDC and reveals cells resistant to activated complement. Leuk Lymphoma.

Baig, Nisar A., Ronald P. Taylor, Margaret A. Lindorfer, Amy K. Church, Betsy R. LaPlant, Emily S. Pavey, Grzegorz S. Nowakowski, and Clive S. Zent. "Complement Dependent Cytotoxicity (CDC) in Chronic Lymphocytic Leukemia (CLL): Ofatumumab Enhances Alemtuzumab CDC and Reveals Cells Resistant to Activated Complement." Leuk Lymphoma 2012.

Baig, Nisar A., et al. "Complement Dependent Cytotoxicity (CDC) in Chronic Lymphocytic Leukemia (CLL): Ofatumumab Enhances Alemtuzumab CDC and Reveals Cells Resistant to Activated Complement." Leuk Lymphoma 2012.